Literature DB >> 24478769

Lack of efflux mediated quinolone resistance in Salmonella enterica serovars Typhi and Paratyphi A.

Sylvie Baucheron1, Isabelle Monchaux1, Simon Le Hello2, François-Xavier Weill2, Axel Cloeckaert1.   

Abstract

Salmonella enterica serovars Typhi and Paratyphi A isolates from human patients in France displaying different levels of resistance to quinolones or fluoroquinolones were studied for resistance mechanisms to these antimicrobial agents. All resistant isolates carried either single or multiple target gene mutations (i.e., in gyrA, gyrB, or parC) correlating with the resistance levels observed. Active efflux, through upregulation of multipartite efflux systems, has also been previously reported as contributing mechanism for other serovars. Therefore, we investigated also the occurrence of non-target gene mutations in regulatory regions affecting efflux pump expression. However, no mutation was detected in these regions in both Typhi and Paratyphi isolates of this study. Besides, no overexpression of the major efflux systems was observed for these isolates. Nevertheless, a large deletion of 2334 bp was identified in the acrS-acrE region of all S. Typhi strains but which did not affect the resistance phenotype. As being specific to S. Typhi, this deletion could be used for specific molecular detection purposes. In conclusion, the different levels of quinolone or FQ resistance in both S. Typhi and S. Paratyphi A seem to rely only on target modifications.

Entities:  

Keywords:  Salmonella; acrS; ciprofloxacin; efflux pumps; transcriptional regulatory genes

Year:  2014        PMID: 24478769      PMCID: PMC3902205          DOI: 10.3389/fmicb.2014.00012

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


Introduction

Enteric fever caused by the human-adapted pathogens Salmonella enterica serovars Typhi (S. Typhi) and Paratyphi A (S. Paratyphi A), B, and C, remains a major health problem (Crump and Mintz, 2010). A global epidemiologic study estimated that during the year 2000 typhoid fever caused 21.7 million illnesses and 21,7000 deaths and paratyphoid fever caused 5.4 million illnesses (Crump et al., 2004). During the past decade S. Paratyphi A was responsible for a growing proportion of enteric fever in Asia (Ochiai et al., 2005; Crump and Mintz, 2010). Enteric fever being associated with poor sanitation and unsafe food and water, it particularly affects children and adolescents in developing countries of Asia, Africa and Latin America (Crump et al., 2004; Bhan et al., 2005; Crump and Mintz, 2010). In developed countries, patients are most often ill-returned travellers or migrant workers (Bhan et al., 2005; Connor and Schwartz, 2005; Hassing et al., 2013). To treat these infections, fluoroquinolones (FQ) and third-generation cephalosporins have been considered as first-line drugs, owing to the resistance to ampicillin, chloramphenicol, and trimethoprim/sulfamethoxazole that appeared during the 1980s (Hassing et al., 2011, 2013). Multidrug resistance (MDR) in S. Typhi is encoded mainly by resistance genes carried by large conjugative plasmids and has been reported worldwide (Le et al., 2007). As a consequence of a widespread FQ usage, S. Typhi and S. Paratyphi A isolates resistant to nalidixic acid (NALR, minimum inhibitory concentration [MIC] > 16 mg/L) and with decreased susceptibility to ciprofloxacin (CIPDS, MIC 0.125–1.0 mg/L) have also emerged. Such NALR-CIPDS S. Typhi and S. Paratyphi A have been isolated in endemic areas and also in developed countries (Roumagnac et al., 2006; Le et al., 2007; Gaborieau et al., 2010; Accou-Demartin et al., 2011; Hassing et al., 2011, 2013). Resistance to quinolones in Salmonella spp. is mostly attributed to point mutations in the quinolone resistance-determining regions (QRDRs) of the target genes gyrA, gyrB, parC, and parE (Cloeckaert and Chaslus-Dancla, 2001; Piddock, 2002; Velge et al., 2005; Giraud et al., 2006). For the gyrA gene, coding the A subunit of DNA gyrase, a single mutation resulting in an amino acid substitution at the position 83 (Serine to Phenylalanine or to Tyrosine) or at the position 87 (Aspartic acid to Asparagine or Glycine) has been the most frequently described in NALR-CIPDS S. Typhi and S. Paratyphi A isolates (Bhan et al., 2005; Renuka et al., 2005; Le et al., 2007; Gaborieau et al., 2010; Hassing et al., 2011). A second mutation leading to the amino acid change at the position 80 (Serine to Isoleucine or to Arginine) of the ParC subunit of topoisomerase IV was described to increase the CIP MIC (≥0.5 mg/L) in S. Typhi and S. Paratyphi A human isolates from India (Gaind et al., 2006). Whereas three mutations, i.e., a double mutation in gyrA at both codons 83 and 87 and one mutation in parC, were shown to confer CIP resistance (MIC >1 mg/L) in S. Typhi and S. Paratyphi A human isolates from India or from Taiwan (Gaind et al., 2006; Lee et al., 2013). Moreover, the varying levels of CIP resistance observed in S. Typhi and S. Paratyphi A isolates with only a single gyrA mutation suggest that other mechanisms could be involved in quinolone resistance in this serovar (Renuka et al., 2005). Resistance to FQ in S. Typhimurium has also been attributed to active efflux mechanism, due to overproduction of the AcrAB-TolC efflux system (Giraud et al., 2000, 2006; Cloeckaert and Chaslus-Dancla, 2001; Piddock, 2006). We have previously reported the contribution of the AcrAB-TolC efflux system in resistance to FQ in several MDR epidemic clones of S. Typhimurium, such as S. Typhimurium of phage types DT204 or DT104 (Baucheron et al., 2002, 2004a,b). Among the chromosomal loci affecting AcrAB-TolC expression, the ramRA locus appears to be the most important in Salmonella spp. (Abouzeed et al., 2008; Kehrenberg et al., 2009). ramR encodes a repressor protein (RamR) belonging to the TetR family of repressor proteins, and has been shown to be the local repressor protein of ramA transcription (Abouzeed et al., 2008; Baucheron et al., 2012); while ramA encodes a transcriptional activator protein (RamA) belonging to the AraC/XylS family of regulatory proteins (Nikaido et al., 2008; Bailey et al., 2010). The latter is involved in upregulating expression of the AcrAB-TolC system (Nikaido et al., 2008; Bailey et al., 2010). Several mutations in ramR or its binding site upstream of ramA, affecting expression of this efflux system, have been detected in clinical isolates of serovar Typhimurium or Kentucky and of minor serovars Hadar, Infantis, Livingstone, or Schwarzengrund (Abouzeed et al., 2008; Kehrenberg et al., 2009; Hentschke et al., 2010; Akiyama and Khan, 2012; Baucheron et al., 2013). In the present study, we have characterized mechanisms involved in resistance to quinolones or fluroquinolones in 21 S. Typhi and S. Paratyphi A strains displaying different levels of resistance to these drugs and isolated from patients in France during the period 1997–2008. For a subset of strains, with suspected increased efflux activity, we investigated the occurrence of mutations in the global ram, sox and mar regulatory loci of AcrAB-TolC, and in the local acrR and acrS repressor genes of the AcrAB and AcrEF pumps, respectively (Abouzeed et al., 2008; Kehrenberg et al., 2009).

Materials and methods

Bacterial strains

The twenty one strains including 16 S. Typhi and 5 S. Paratyphi A selected for this study were collected by the French National Reference Center for Salmonella, Institut Pasteur, Paris, France. They were isolated in France from travellers or migrants between 1997 and 2008 (Table 1). The selection was made to obtain diversity in terms of geographic origin, year of isolation, genetic lineages (haplotype for S. Typhi; Roumagnac et al., 2006), and phenotype of resistance to quinolones (Table 1).
Table 1

.

StrainCountryYear of isolationHaplo typeAntimicrobial resistance patternMIC (mg/L)Substitution(s) in the QRDR of:AcrA production ratio*
NALCIPGyrAGyrBParCParE
SALMONELLA TYPHI
06–423India2006NDPansusceptible40.015WTWTWTWT1
06–426India2006NDCIPDS160.125WTS464YWTWT1
02–1180India2002H45NALCIPDS640.125D87GWTWTWT1
05–3275Morocco2005H6NALCIPDS640.125D87NWTWTWT1
4(02)MBVietnam1997H58ASCSulTmpTeNAL1280.03S83YWTWTWT0.5
222(97)MNVietnam1996NDASCSulTmpTeNALCIPDS1280.125S83FWTWTWT0.5
43(97)MNVietnam1996H63ASCSulTmpTeNALCIPDS1280.125S83FWTWTWT0.5
98–3139Mexico1998H50NALCIPDS1280.125S83FWTWTWT0.5
02–7744India2002H52NALCIPDS1280.125S83FWTWTWT0.5
226(97)MNVietnam1996H61ASCSulTmpTeNALCIPDS1280.25S83FWTWTWT0.5
97–2307India1997H63NALCIPDS2560.125S83FWTWTWT0.5
318(98)MBVietnam1998H58ASCSulTmpTeNALCIPDS5120.25S83YWTWTWT1
39(98)MNVietnam1998H58ASCSulTmpTeNALCIPDS5120.25S83FWTWTWT1
4(02)MNVietnam2000H58ASCSulTmpTeNALCIPDS10240.25S83FWTWTD420N1
5(04)MNVietnam2004NDNALCIPDS10240.25S83FWTWTD420N1
04–2176India2004H58SSpSulTmpTeNALCIP10248S83F; D87NWTS80IWT1
SALMONELLA PARATYPHI A
08–8903Senegal2008Pansusceptible80.030WTWTWTWT2
07–6329Burkina Faso2007CIPDS160.25WTS464FWTWT2
05–208India2005NALCIPDS2560.50S83FWTWTWT2
08–4271Guinea Bissau2008NACIPDS10241S83FWTWTWT2
08–2580India2008NALCIPDS10241S83FWTWTWT3

AcrA expression was measured by dot blotting with an anti-AcrA polyclonal antibody.

ND, not determined.

WT, wild type.

A, amoxicillin; S, streptomycin; Sp, spectinomycin; C, chloramphenicol; Sul, sulfamethoxazole; Tmp, trimethoprim; Te, tetracycline; NAL, nalidixic acid; CIP, ciprofloxacin; CIPDS, decreased susceptibility to ciprofloxacin.

D, aspartic acid; F, phenylalanine; G, glycine; I, isoleucine; N, asparagine; S, serine; Y, tyrosine.

. AcrA expression was measured by dot blotting with an anti-AcrA polyclonal antibody. ND, not determined. WT, wild type. A, amoxicillin; S, streptomycin; Sp, spectinomycin; C, chloramphenicol; Sul, sulfamethoxazole; Tmp, trimethoprim; Te, tetracycline; NAL, nalidixic acid; CIP, ciprofloxacin; CIPDS, decreased susceptibility to ciprofloxacin. D, aspartic acid; F, phenylalanine; G, glycine; I, isoleucine; N, asparagine; S, serine; Y, tyrosine.

Antimicrobial susceptibility testing

Antimicrobial susceptibility was investigated by the standard disk diffusion method according to the recommendations of the Antibiogram Committee of the French Society for Microbiology (CA-SFM) (www.sfm-microbiologie.org/). The MICs of NAL and CIP were determined by the standard agar doubling dilution method as described previously (Baucheron et al., 2002). The NALR isolates were defined as having a MIC > 16 mg/L. The CIPR isolates were defined as having a MIC > 1 mg/L and CIPDS isolates as having a MIC comprised between 0.125 and 1.0 mg/L (Accou-Demartin et al., 2011; Hassing et al., 2013). MICs of these antibiotics were also determined in the presence of the efflux pump inhibitor Phe-Arg-β-naphthylamide (PAβ N, Sigma) at the following concentrations: 10, 20, 30, 40, 50, and 60 mg/L.

Assessment of target-affecting mechanisms

Mutations in the QRDRs of gyrA, gyrB, parC, and parE genes were detected as described previously (Le et al., 2007; Song et al., 2010; Accou-Demartin et al., 2011). The search of plasmid-mediated quinolone resistances genes, qnrA, qnrB, qnrS, qnrD, aac(6')-Ib-cr, and qepA was performed as described previously (Accou-Demartin et al., 2011).

Assessment of efflux mechanisms

Efflux pump production was assessed by dot blot using an anti-AcrA polyclonal antibody as described previously (Abouzeed et al., 2008). Occurrence of mutations affecting acrAB, acrEF, and tolC expression was determined by PCR and sequencing the regulatory regions ramR-ramA, acrR-acrA, marC-marO-marR-marA, soxS-soxR, and acrS-acrE using primers listed in (Table 2). Transcription levels of efflux related genes acrA, acrB, acrF, tolC, ramA, and ramR were done by quantitative reverse transcription-PCR (qRT-PCR) as described previously (Baucheron et al., 2012; Giraud et al., 2013). Primers used for qRT-PCR are listed in (Table 2).
Table 2

Primers used for PCRs.

Primer used and target regionPrimerNucleotide position relative to the LT2 strain genome sequence*Oligonucleotide sequence(s) (5'–3')Size (bp)Annealing temp (°C)Reference
DETECTION OF MUTATIONS
ramR-ramAram5638085TCGGTAAAAGGCAGTTCCAG95860Baucheron et al., 2013
ramA6639042GTCGATAACCTGAGCGGAAA
acrR-acrAacrR1533463CAGTGGTTCCGTTTTTAGTG99258Olliver et al., 2005
acrR2534454ACAGAATAGCGACACAGAAA
marC-marO-marR-marAmarR11597459CAGTGTTGCGTCTGGACATC78760Baucheron et al., 2013
marR21598245GCTAACGGGAGCAGTACGAC
soxS-soxRsox14503970CTACAGGCGGTGACGGTAAT91560Baucheron et al., 2013
sox24504884CGGCGCTTTAGTTTTAGGTG
acrS-acrEacrS33559106AAAACGAACGGGAACTGATG2874 ***58This study
acrS43561978ACAAACATACCGGGAAGCAG
qRT-PCR
gmkgmk-f3933294TTGGCAGGGAGGCGTTT6260Baucheron et al., 2012
gmk-r3933355GCGCGAAGTGCCGTAGTAAT
gyrBgyrB-f4040275TCTCCTCACAGACCAAAGATAAGCT8160Baucheron et al., 2012
gyrB-r4040195CGCTCAGCAGTTCGTTCATC
rrsrrs-fNA**CCAGCAGCCGCGGTAAT5760Baucheron et al., 2012
rrs-rNA**TTTACGCCCAGTAATTCCGATT
ramAramA-f639180GCGTGAACGGAAGCTAAAAC16760Baucheron et al., 2012
ramA-r639346GGCCATGCTTTTCTTTACGA
ramRramR-f638623TAACGCAGGTGTTGCAGAAG19264Baucheron et al., 2012
ramR-r638432TGGTTCAGACCCCAACTGAT
acrAacrA-f533120GAAACCGCACGTATCAACCT22060Baucheron et al., 2012
acrA-r532901CCTGTTTCAGCGAACCATTT
acrBacrB-f531348TCGTGTTCCTGGTGATGTACCT6866Baucheron et al., 2012
acrB-r531281AACCGCAATAGTCGGAATCAA
acrFacrF-f3563042GCTCTGTCGTCCATCTCAAAGA7066This study
acrF-r3563111CGCGCTACAACGTTATAGTTTTCA
tolCtolC-f3349107GCCCGTGCGCAATATGAT6760Baucheron et al., 2012
tolC-r3349173CCGCGTTATCCAGGTTGTTG

GenBank NC_003197.1.

NA: Not Applicable due to the number of copies of this gene in Salmonella.

2874 bp for S. Typhimurium or S. Paratyphi A and 539 bp for S. Typhi (see Figure 1).

Primers used for PCRs. GenBank NC_003197.1. NA: Not Applicable due to the number of copies of this gene in Salmonella. 2874 bp for S. Typhimurium or S. Paratyphi A and 539 bp for S. Typhi (see Figure 1).
Figure 1

Deletion identified in the The sequence of the acrSE region of S. Typhi strain CT18 is compared to those of S. Paratyphi A strain ATCC9150 (GenBank NC_006511.1) and S. Typhi strain LT2 (GenBank NC_003197.1). Small black arrows indicate primers positions used for PCR to amplify and sequence the acrSE region. The 2334 bp chromosomal deletion was found in all S. Typhi strains studied.

Results and discussion

Resistance phenotypes and target-affecting mechanisms

The twenty one S. Typhi and S. Paratyphi A strains of this study were isolated in France but acquired abroad, mainly in Asia and Africa (Table 1). Among the S. Typhi strains, all but two were NALR (MIC > 16 mg/L). One of the two strains was pansusceptible and the second was CIPDS but only categorized as intermediate for NAL (NALI, MIC 16 mg/L). Of the 14 NALR strains, one was CIP, 12 were CIPDS and one was CIPS (MIC 0.03 mg/L). Eight NALR S. Typhi strains were also multidrug resistant. The majority of the NALR S. Typhi strains belonged to haplotype H58 which had emerged in Southern Asia during the mid 1990s (Roumagnac et al., 2006; Le et al., 2007). Among the S. Paratyphi A strains, all but two were NALR. One of the two strains was pansusceptible and the second was NALI-CIPDS. The three others were NALR- CIPDS. As shown in Table 1, both NALI-CIPDS had a mutation resulting in an amino acid substitution at position 464 of GyrB: serine to tyrosine for the S. Typhi isolate and serine to phenylalanine for the S. Paratyphi A isolate. The most frequent mechanism of resistance of NALR-CIPDS (n = 17) and NALR-CIP (n = 1) strains, whatever the serovar, was a substitution at position 83 (serine to phenylalanine, n = 12, 66.6%) of GyrA. Other GyrA modifications were observed at position 83 (serine to tyrosine) in two isolates or at position 87 (aspartic acid to glycine, aspartic acid to asparagine) in one isolate for each. As described previously, a single substitution in GyrA was associated with resistance to nalidixic acid and decreased susceptibility to CIP (Bhan et al., 2005; Le et al., 2007; Gaborieau et al., 2010; Hassing et al., 2011). One exception was the S. Typhi strain 4 (02) MB, which was NALR-CIPS (and not CIPDS) despite a mutation in gyrA resulting in substitution serine to tyrosine at position 83. Additional substitutions were found in ParE of 2 NALR-CIPDS S. Typhi strains that led to amino acid substitution aspartic acid to asparagine at position 420. In both cases, a 2-fold increase of NAL MICs was observed. In the CIPR S. Typhi isolate, three mutations leading to a double substitution in GyrA at positions 83 (serine to phenylalanine) and 87 (aspartic acid to asparagine) and one substitution at the position 80 of ParC (serine to isoleucine), as observed in previous studies (Renuka et al., 2005; Gaind et al., 2006; Lee et al., 2013). The NALR and CIPDS S. Typhi and S. Paratyphi A strains harboring a single substitution in GyrA showed various values for NAL (64–1024 mg/L) and CIP (0.03–0.5 mg/L) MICs which suggested the presence of other mechanisms of resistance. Since the plasmid-mediated quinolone resistance-conferring genes qnrA, qnrB, qnrD or qnrS, qepA, and aac(6')-Ib-cr were not detected, we investigated the role of the AcrAB-TolC efflux system.

Involvement of efflux

None of the S. Typhi strains showed significant AcrA overproduction by dot blot, but nevertheless all S. Paratyphi A isolates showed a 2 or 3-fold increased AcrA production relative to the susceptible S. Typhi isolate (Table 1). Thus, overproduction of AcrA seems not to be involved in CIPDS isolates compared with the susceptible isolates of S. Typhi or S. Paratyphi A. In presence of the efflux pump inhibitor PAβ N (20 or 40 mg/L), the CIP MICs similarly decreased (4 or 8-fold) in CIPDS and in susceptible strains (Table 3 and data not shown), which is in accordance with previous studies on S. Typhimurium and corresponds to a decrease of resistance level observed for acrB or tolC deletion mutants (Baucheron et al., 2002, 2004b).
Table 3

Study of efflux in a subset of .

StrainAntimicrobial resistance patternaMIC (mg/L)bSubstitution(s) in the QRDR of c:acrSE sequencingTranscription level of:
NALCIPGyrAGyrBParCParEacrAacrFacrBtolCramAramR
SALMONELLA TYPHI
06–423Pansusceptible40.015 [0.004]WTWTWTWTDeletiond1.01.01.01.01.01.0
02–1180NALCIPDS640.125 [0.015]D87GWTWTWTDeletiond1.50.70.50.80.91.4
05–3275NALCIPDS640.125 [0.030]D87NWTWTWTDeletiond0.51.40.20.50.30.7
97–2307NALCIPDS2560.125 [0.030]S83FWTWTWTDeletiond1.70.80.80.71.92.2
04–2176SSpSulTmpTeNALCIP10248 [2]S83F; A87NWTS80IWTDeletiond1.50.81.30.91.22.2
SALMONELLA PARATYPHI A
08–8903Pansusceptible80.030 [0.008]WTWTWTWTWT1.01.01.01.01.01.0
07–6329CIPDS160.25 [0.060]WTS464FWTWTWT1.61.41.01.01.01.2
05–208NALCIPDS2560.50 [0.030]S83FWTWTWTWT1.30.91.41.01.11.0
08–4271NALCIPDS10241 [0.25]S83FWTWTWTWT1.21.10.71.41.31.3
08–2580NALCIPDS10241 [0.25]S83FWTWTWTWT2.01.61.41.42.01.3

S, streptomycin; Sp, spectinomycin; Sul, sulfamethoxazole; Tmp, trimethoprim; Te, tetracycline; NAL, nalidixic acid; CIP, ciprofloxacin; CIPDS, decreased susceptibility to ciprofloxacin.

Values in brackets are MICs in the presence of the efflux pump inhibitor PAβ N at 40 mg/L.

WT, wild type; D, aspartic acid; F, phenylalanine; G, glycine; I, isoleucine; N, asparagine; S, serine.

2334 bp deleted.

Study of efflux in a subset of . S, streptomycin; Sp, spectinomycin; Sul, sulfamethoxazole; Tmp, trimethoprim; Te, tetracycline; NAL, nalidixic acid; CIP, ciprofloxacin; CIPDS, decreased susceptibility to ciprofloxacin. Values in brackets are MICs in the presence of the efflux pump inhibitor PAβ N at 40 mg/L. WT, wild type; D, aspartic acid; F, phenylalanine; G, glycine; I, isoleucine; N, asparagine; S, serine. 2334 bp deleted. Despite a lack of evidence of increased efflux in the resistance phenotype, we measured by qRT-PCR the transcription levels of efflux related genes acrA, acrF, acrB, tolC, ramA, and ramR in CIPDS non-MDR strains and in the CIPR strain. No differences were detected in the transcription levels of these genes, between susceptible, CIPDS and CIPR strains, whatever the serovar (Table 3). In addition, no mutations were detected in the regulatory regions of the AcrAB-TolC efflux system. However, during the screening of the regulatory regions, we identified a single large deletion of 2334 bp in the acrS-acrE region of all S. Typhi strains, including the susceptible one (Table 3). This deletion encompassed the acrS gene, that encodes a transcriptional repressor, and a large part of the acrE gene that encodes the AcrE periplasmic lipoprotein, which is homologous to AcrA (Olliver et al., 2005). This 2334 bp deletion was also observed in the acrS-acrE region of sequenced genomes of MDR S. Typhi CT18 strain (Parkhill et al., 2001) and pansusceptible TY2 strain (Deng et al., 2003) (Figure 1). Previously, it has been shown that acrS deletion in S. Typhimurium does not affect acrEF expression (Olliver et al., 2005). Similarly the natural acrSE deletion detected in S. Typhi had no impact on the acrF transcription level as observed in this study. To our knowledge, this is the first description of such a natural acrS-acrE chromosomal deletion and seems specific to S. Typhi since it was not detected in all currently sequenced genomes of the other serovars (not shown). Deletion identified in the The sequence of the acrSE region of S. Typhi strain CT18 is compared to those of S. Paratyphi A strain ATCC9150 (GenBank NC_006511.1) and S. Typhi strain LT2 (GenBank NC_003197.1). Small black arrows indicate primers positions used for PCR to amplify and sequence the acrSE region. The 2334 bp chromosomal deletion was found in all S. Typhi strains studied.

Conclusions

The main mechanisms involved in quinolone or FQ resistance in both S. Typhi and S. Paratyphi A are target modifications. In contrast to what is seen in enteric pathogenic serovars, such as Typhimurium or the emerging CIPR Kentucky ST198 clone (Baucheron et al., 2013), increased efflux pump production-mediated mechanisms seem to be totally absent in both S. Typhi and S. Paratyphi A. The deletion identified in the acrSEF region, although not involved in the resistance phenotype, may be helpful for the specific detection of S. Typhi.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  36 in total

1.  Overexpression of the multidrug efflux operon acrEF by insertional activation with IS1 or IS10 elements in Salmonella enterica serovar typhimurium DT204 acrB mutants selected with fluoroquinolones.

Authors:  Anne Olliver; Michel Vallé; Elisabeth Chaslus-Dancla; Axel Cloeckaert
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 2.  Mechanisms of quinolone resistance in Salmonella.

Authors:  A Cloeckaert; E Chaslus-Dancla
Journal:  Vet Res       Date:  2001 May-Aug       Impact factor: 3.683

3.  Effects of natural mutations in the ramRA locus on invasiveness of epidemic fluoroquinolone-resistant Salmonella enterica serovar Typhimurium isolates.

Authors:  Etienne Giraud; Sylvie Baucheron; Isabelle Virlogeux-Payant; Kunihiko Nishino; Axel Cloeckaert
Journal:  J Infect Dis       Date:  2012-12-10       Impact factor: 5.226

4.  Binding of the RamR repressor to wild-type and mutated promoters of the RamA gene involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.

Authors:  Sylvie Baucheron; Franck Coste; Sylvie Canepa; Marie-Christine Maurel; Etienne Giraud; Françoise Culard; Bertrand Castaing; Alain Roussel; Axel Cloeckaert
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

5.  Analysis of mechanisms involved in reduced susceptibility to ciprofloxacin in Salmonella enterica serotypes Typhi and Paratyphi A isolates from travellers to Southeast Asia.

Authors:  Robert-Jan Hassing; Godfred A Menezes; Wilfred van Pelt; Pieter L Petit; Perry J van Genderen; Wil H F Goessens
Journal:  Int J Antimicrob Agents       Date:  2011-01-11       Impact factor: 5.283

6.  RamA, a member of the AraC/XylS family, influences both virulence and efflux in Salmonella enterica serovar Typhimurium.

Authors:  Andrew M Bailey; Al Ivens; Rob Kingsley; Jennifer L Cottell; John Wain; Laura J V Piddock
Journal:  J Bacteriol       Date:  2010-01-15       Impact factor: 3.490

7.  First isolation of ciprofloxacin-resistant Salmonella enterica serovar Typhi in Taiwan.

Authors:  Chia-Jie Lee; Lin-Hui Su; Yhu-Chering Huang; Cheng-Hsun Chiu
Journal:  J Microbiol Immunol Infect       Date:  2013-03-05       Impact factor: 4.399

8.  The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in Salmonella enterica serovar typhimurium phage type DT204.

Authors:  Sylvie Baucheron; Hein Imberechts; Elisabeth Chaslus-Dancla; Axel Cloeckaert
Journal:  Microb Drug Resist       Date:  2002       Impact factor: 3.431

9.  Salmonella paratyphi A rates, Asia.

Authors:  R Leon Ochiai; XuanYi Wang; Lorenz von Seidlein; Jin Yang; Zulfiqar A Bhutta; Sujit K Bhattacharya; Magdarina Agtini; Jacqueline L Deen; John Wain; Deok Ryun Kim; Mohammad Ali; Camilo J Acosta; Luis Jodar; John D Clemens
Journal:  Emerg Infect Dis       Date:  2005-11       Impact factor: 6.883

10.  Salmonella enterica Serotype Typhi with nonclassical quinolone resistance phenotype.

Authors:  Marie Accou-Demartin; Valérie Gaborieau; Yajun Song; Philippe Roumagnac; Bruno Marchou; Mark Achtman; François-Xavier Weill
Journal:  Emerg Infect Dis       Date:  2011-06       Impact factor: 6.883

View more
  5 in total

1.  Molecular level understanding of resistance to nalidixic acid in Salmonella enteric serovar typhimurium associates with the S83F sequence type.

Authors:  B Preethi; K Ramanathan
Journal:  Eur Biophys J       Date:  2015-09-02       Impact factor: 1.733

2.  A Multicountry Molecular Analysis of Salmonella enterica Serovar Typhi With Reduced Susceptibility to Ciprofloxacin in Sub-Saharan Africa.

Authors:  Hassan M Al-Emran; Daniel Eibach; Ralf Krumkamp; Mohammad Ali; Stephen Baker; Holly M Biggs; Morten Bjerregaard-Andersen; Robert F Breiman; John D Clemens; John A Crump; Ligia Maria Cruz Espinoza; Jessica Deerin; Denise Myriam Dekker; Amy Gassama Sow; Julian T Hertz; Justin Im; Samuel Ibrango; Vera von Kalckreuth; Leon Parfait Kabore; Frank Konings; Sandra Valborg Løfberg; Christian G Meyer; Eric D Mintz; Joel M Montgomery; Beatrice Olack; Gi Deok Pak; Ursula Panzner; Se Eun Park; Jean Luco Tsiriniaina Razafindrabe; Henintsoa Rabezanahary; Jean Philibert Rakotondrainiarivelo; Raphaël Rakotozandrindrainy; Tiana Mirana Raminosoa; Heidi Schütt-Gerowitt; Emmanuel Sampo; Abdramane Bassiahi Soura; Adama Tall; Michelle Warren; Thomas F Wierzba; Jürgen May; Florian Marks
Journal:  Clin Infect Dis       Date:  2016-03-15       Impact factor: 9.079

3.  Mechanisms of antibiotic resistance.

Authors:  Jun Lin; Kunihiko Nishino; Marilyn C Roberts; Marcelo Tolmasky; Rustam I Aminov; Lixin Zhang
Journal:  Front Microbiol       Date:  2015-02-05       Impact factor: 5.640

4.  Antimicrobial susceptibility of travel-related Salmonella enterica serovar Typhi isolates detected in Switzerland (2002-2013) and molecular characterization of quinolone resistant isolates.

Authors:  Magdalena Nüesch-Inderbinen; Helga Abgottspon; Grethe Sägesser; Nicole Cernela; Roger Stephan
Journal:  BMC Infect Dis       Date:  2015-05-12       Impact factor: 3.090

Review 5.  Molecular epidemiology of fluoroquinolone resistant Salmonella in Africa: A systematic review and meta-analysis.

Authors:  Getachew Tadesse; Tesfaye S Tessema; Getenet Beyene; Abraham Aseffa
Journal:  PLoS One       Date:  2018-02-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.